Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.2%
0%
-14.2%
6 Months
-33.71%
0%
-33.71%
1 Year
-32.63%
0%
-32.63%
2 Years
-37.18%
0%
-37.18%
3 Years
-26.71%
0%
-26.71%
4 Years
-39.2%
0%
-39.2%
5 Years
0%
0%
0.0%
SKAN Group AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.33%
EBIT Growth (5y)
-5.68%
EBIT to Interest (avg)
13.54
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.33
Tax Ratio
0
Dividend Payout Ratio
23.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.32%
ROE (avg)
17.55%
Valuation key factors
Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
6.70
EV to EBIT
88.57
EV to EBITDA
88.57
EV to Capital Employed
9.13
EV to Sales
81.95
PEG Ratio
38.59
Dividend Yield
35.28%
ROCE (Latest)
10.31%
ROE (Latest)
17.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
277.00
236.00
17.37%
Operating Profit (PBDIT) excl Other Income
40.20
32.40
24.07%
Interest
1.10
0.60
83.33%
Exceptional Items
0.00
-1.50
100.00%
Consolidate Net Profit
21.40
21.40
Operating Profit Margin (Excl OI)
106.40%
104.90%
0.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 17.37% vs 23.11% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is 0.00% vs 84.48% in Dec 2021
About SKAN Group AG 
SKAN Group AG
Pharmaceuticals & Biotechnology
BV Holding AG is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland and bordering countries. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholders’ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.
Company Coordinates 
Company Details
Hofgut, Vordere Dorfgasse 12 , GUEMLIGEN None : 3073
Registrar Details






